 |
Achillion to Present at the Wells Fargo 2013 Healthcare Conference
Jun 12, 2013
|
8.0 KB |
|
| |
NEW HAVEN, Conn., June 12, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, President and Chief Executive Officer of Achillion, and members of the senior management team will present a corporate update and participate on a HCV Panel at the Wells Fargo 2013 Healthcare Conference on Tuesday...
|
|
Achillion Nominates ACH-3422 as Nucleotide for the Treatment of Chronic HCV
May 30, 2013
|
14.7 KB |
|
| |
— Advancement of ACH-3422 Complements Achillion's Portfolio of 2nd Generation Protease and NS5A Inhibitors Providing the Opportunity to Optimize Treatment Duration and Outcomes for All HCV Patients — — Conference Call and Webcast to be Hosted Today at 12:00pm EDT —
NEW HAVEN, Conn., May 30, 2013 (GLOBE NEWSWIRE) -- Achi...
|
|
Achillion Names Milind Deshpande, Ph.D., as President, Chief Executive Officer, Following Announced Retirement of Michael Kishbauch
May 28, 2013
|
11.1 KB |
|
| |
NEW HAVEN, Conn., May 28, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that President and Chief Executive Officer Michael D. Kishbauch has decided to retire. In conjunction with this decision, the Board has appointed President of Research and Development and Chief Scientific Officer, Milind Deshpande, Ph.D....
|
|
Achillion Appoints Dr. David Apelian as Chief Medical Officer and Expands Clinical Operations Team
May 15, 2013
|
13.1 KB |
|
| |
NEW HAVEN, Conn., May 15, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the appointment of David Apelian, M.D., Ph.D., MBA, to the position of Executive Vice President and Chief Medical Officer, effective May 28, 2013. Dr. Apelian wll assume responsibility for the clinical development of Achillion's portfoli...
|
|
Achillion to Present at Three Upcoming Investor Conferences
May 9, 2013
|
9.0 KB |
|
| |
NEW HAVEN, Conn., May 9, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that members of the senior management team will be presenting a company overview at three upcoming investor conferences:
Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15, 2013 at 3:00 p.m. PT at the Enco...
|
|
Achillion Reports First Quarter 2013 Financial Results
May 7, 2013
|
14.5 KB |
|
| |
NEW HAVEN, Conn., May 7, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended March 31, 2013. For the first quarter of 2013, the Company reported a net loss of $11.7 million or $0.14 per share, compared with a net loss of $9.1 million or $0.13 per share for the first quar...
|
|
Achillion Presents New Data on ACH-3102 to Treat Hepatitis C at the International Liver Congress
Apr 23, 2013
|
18.0 KB |
|
| |
- Phase 1 Results Further Demonstrate Potency of ACH-3102 in Genotypes 1a and 1b and Against Resistant HCV-- Study Shows ACH-3102 and Sovaprevir Can be Co-Administered Without Interaction -- Total of Six Poster Presentations to be Made During EASL -
AMSTERDAM, The Netherlands, April 23, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (...
|
|
Achillion Announces Updated Phase 2 Results Including Early Sustained Virologic Response on ACH-3102 Plus Ribavirin in Genotype 1b Treatment-Naive Hepatitis C Patients
Apr 23, 2013
|
14.8 KB |
|
| |
- ACH-3102 deemed safe and well-tolerated following 12 weeks of therapy - - High barrier to resistance demonstrated with no on-treatment virologic breakthrough observed - - Novel NS5A inhibitor study supports differentiated profile of ACH-3102 -
NEW HAVEN, Conn., April 23, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) ...
|
|
Achillion Initiates Phase 2 Interferon-Free Trial of Sovaprevir and ACH-3102 for Genotype 1 HCV
Apr 16, 2013
|
12.6 KB |
|
| |
NEW HAVEN, Conn., April 16, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it has initiated an international Phase 2 clinical trial with sovaprevir and ACH-3102 for the treatment of genotype 1 chronic hepatitis C (HCV). The trial will evaluate an all-oral 12-week interferon-free regimen consisting of sov...
|
|
Achillion to Present at Two Upcoming Investor Conferences
Mar 1, 2013
|
8.9 KB |
|
| |
NEW HAVEN, Conn., March 1, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that members of the senior management team will be presenting a company overview at two upcoming investor conferences:
Cowen and Company 33rd Annual Health Care Conference on Monday, March 4, 2013 at 2:50 p.m. ET at The Boston Marr...
|
|
Achillion Pharmaceuticals Announces Closing of Public Offering
Feb 27, 2013
|
10.3 KB |
|
| |
NEW HAVEN, Conn., Feb. 27, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that the underwriters exercised their option to purchase an additional 1,894,410 shares from Achillion in its previously announced underwritten public offering of common stock at a price to the public of $8.40 per share. The offering of...
|
|
Achillion Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Feb 21, 2013
|
10.1 KB |
|
| |
NEW HAVEN, Conn., Feb. 21, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $8.40 per share. The net proceeds to Achillion from the sale of the shares, after deducting underwriting discounts and c...
|
|
Achillion Reports 2012 Fourth Quarter and Year-End Financial Results
Feb 20, 2013
|
19.8 KB |
|
| |
- Conference call and webcast to be held today, February 20th, at 5:00 pm EST -
NEW HAVEN, Conn., Feb. 20, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and twelve months ended December 31, 2012.
For the three months ended December 31, 2012, the Company reported a net l...
|
|
Achillion Pharmaceuticals Announces Proposed Public Offering of Common Stock
Feb 20, 2013
|
10.9 KB |
|
| |
NEW HAVEN, Conn., Feb. 20, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that it has commenced an underwritten public offering of $125 million of its common stock. In connection with this offering, Achillion plans to grant the underwriters a 30-day option to purchase additional shares of its common stock. Ci...
|
|
Achillion to Report Fourth Quarter and Year End 2012 Financial Results and Host Conference Call on February 20, 2013
Feb 19, 2013
|
9.5 KB |
|
| |
NEW HAVEN, Conn., Feb. 19, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it plans to release fourth quarter and year-end 2012 financial results on Wednesday, February 20, 2013, after the market closes. Achillion will also host a conference call and live webcast to discuss these financial results and to ...
|
|
Achillion to Present at the 2013 Leerink Swann Global Healthcare Conference
Feb 8, 2013
|
8.0 KB |
|
| |
NEW HAVEN, Conn., Feb. 8, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Michael Kishbauch, President and Chief Executive Officer of Achillion, will present a corporate update at the Leerink Swann Global Healthcare Conference on Wednesday, February 13, 2013 at 3:30 p.m. EST at the Waldorf-Astoria Hotel i...
|
|
Achillion to Present at the Noble Financial Capital Markets' Ninth Annual Equity Conference
Jan 17, 2013
|
8.0 KB |
|
| |
NEW HAVEN, Conn., Jan. 17, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Joseph Truitt, Senior Vice President of Business Development and Chief Commercial Officer of Achillion, will present a corporate update at the upcoming Noble Financial Capital Markets' Ninth Annual Equity Conference on Wednesday, J...
|
|
Achillion Reports Interim Results on ACH-3102
Jan 7, 2013
|
15.3 KB |
|
| |
- Enrollment completed in pilot Phase 2a study of ACH-3102 and ribavirin for genotype 1b CC patients -- Up to 12 weeks of once daily ACH-3102 appears safe and well tolerated with no on-treatment virologic breakthrough observed to date -- Profile of ACH-3102 supportive of continued development for genotype 1b and in combination with other direct-act...
|
|
Achillion to Present at Two Upcoming Investor Conferences
Nov 30, 2012
|
8.2 KB |
|
| |
NEW HAVEN, Conn., Nov. 30, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the senior management team will present at the following investor conferences during the month of December:
Deutsche Bank 2012 dbAccess BioFEST Conference on Monday, December 3, 2012 at 11:20 a.m. EST at the Four Se...
|
|
Achillion to Present at Two Upcoming Investor Conferences
Nov 13, 2012
|
8.0 KB |
|
| |
NEW HAVEN, Conn., Nov. 13, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the senior management team will present at the following investor conferences during the month of November:
2012 Credit Suisse Healthcare Conference on Thursday, November 15, 2012 at 1:00 p.m. MT at the Arizona Bilt...
|
|
|
